ATP‐competitive inhibitors indirubin, hymenialdisin, and SB216763 can inhibit GSK‐3β enzyme activity, alleviate Aβ deposition and tau hyperphosphorylation‐associated neuropathological changes, and improve cognitive impairment in AD animal models.113, 114. The gene discussed is MAPT; the disease is Alzheimer disease.